Company research
Apellis Pharmaceuticals, Inc.
CIK 1492422Updated Sep 26, 2026
SecurityAPLS · NASDAQ · equity
APLS price & chart
Loading TradingView…
NASDAQ:APLS on TradingView ↗About the company
Apellis is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.
In the news
Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders ↗
Shareholder Alert: The Ademi Firm investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders ↗
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,075,257,000Source | 885,051,000Source | 788,730,000Source | 760,217,000Source |
| Property, Plant and Equipment, NetUSD | 1,708,000Source | 2,952,000Source | 4,345,000Source | 6,148,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 466,233,000Source | 411,290,000Source | 351,185,000Source | 551,801,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 366,221,000Source | 264,926,000Source | 206,442,000Source | 7,727,000Source |
| Inventory, NetUSD | 142,556,000Source | 81,404,000Source | 146,362,000Source | 85,714,000Source |
| Assets, CurrentUSD | 1,014,840,000Source | 788,954,000Source | 766,331,000Source | 719,523,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 38,303,000Source | — | — | — |
| Operating Lease, Right-of-Use AssetUSD | 18,195,000Source | 16,083,000Source | 16,745,000Source | 18,747,000Source |
| Other Assets, NoncurrentUSD | 5,555,000Source | 1,349,000Source | 1,309,000Source | 15,799,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 705,110,000Source | 656,512,000Source | 594,209,000Source | 590,345,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 12,000Source | 12,000Source | 12,000Source | 11,000Source |
| Additional Paid in CapitalUSD | 3,385,216,000Source | 3,267,201,000Source | 3,035,539,000Source | 2,479,596,000Source |
| Retained Earnings (Accumulated Deficit)USD | -3,012,978,000Source | -3,035,366,000Source | -2,837,488,000Source | -2,308,860,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,103,000Source | -3,308,000Source | -3,542,000Source | -875,000Source |
| Stockholders' Equity Attributable to ParentUSD | 370,147,000Source | 228,539,000Source | 194,521,000Source | 169,872,000Source |
| Liabilities and EquityUSD | 1,075,257,000Source | 885,051,000Source | 788,730,000Source | 760,217,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 323,596,000Source | 185,509,000Source | 247,593,000Source | 167,610,000Source |
| Operating Lease, Liability, CurrentUSD | 7,087,000Source | 6,753,000Source | 6,441,000Source | 5,625,000Source |
| Accounts Payable, CurrentUSD | 56,798,000Source | 38,572,000Source | 37,516,000Source | 37,342,000Source |
| Operating Lease, Liability, NoncurrentUSD | 11,947,000Source | 10,201,000Source | 11,454,000Source | 14,352,000Source |
| Other Liabilities, NoncurrentUSD | 7,903,000Source | 7,972,000Source | 2,312,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 166,049,000Source | 140,184,000Source | 127,806,000Source | 95,139,000Source |
| Long-term DebtUSD | — | — | 93,033,000Source | 92,736,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 22,388,000Source | -197,878,000Source | -528,628,000Source | -652,172,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 104,003,000Source | 114,128,000Source | 105,945,000Source | 91,085,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 101,279,000Source | 58,484,000Source | 198,715,000Source | -2,375,000Source |
| Increase (Decrease) in InventoriesUSD | 15,267,000Source | 10,755,000Source | 60,647,000Source | 69,397,000Source |
| Increase (Decrease) in Accounts PayableUSD | 18,223,000Source | 1,089,000Source | 170,000Source | 18,689,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 45,327,000Source | -87,866,000Source | -594,735,000Source | -513,745,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -313,000Source | -403,000Source | -674,000Source | 59,893,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 313,000Source | 403,000Source | 773,000Source | 1,524,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 11,000Source | 57,000Source | 11,040,000Source | 5,682,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 8,884,000Source | 149,241,000Source | 394,499,000Source | 365,659,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 55,148,000Source | 60,313,000Source | -200,775,000Source | -88,681,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 467,760,000Source | 412,612,000Source | 352,299,000Source | 553,074,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 41,233,000Source | 29,368,000Source | 3,286,000Source | 5,003,000Source |
| Income Taxes Paid, NetUSD | 1,631,000Source | — | — | 4,915,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,250,000Source | -659,000Source | 135,000Source | -488,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 104,003,000Source | 114,128,000Source | 105,945,000Source | 91,085,000Source |
| DepreciationUSD | 1,558,000Source | 1,797,000Source | 1,784,000Source | 1,552,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | -120,000Source | — |
| General and Administrative ExpenseUSD | — | — | 500,815,000Source | 277,163,000Source |
| Income Tax Expense (Benefit)USD | 1,722,000Source | 1,162,000Source | 2,132,000Source | 669,000Source |
| InterestExpenseNonoperatingUSD | 44,327,000Source | 40,391,000Source | — | — |
| Inventory Write-downUSD | 20,500,000Source | 19,000,000Source | 6,400,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | 22,388,000Source | -197,878,000Source | -528,628,000Source | -652,172,000Source |
| Operating ExpensesUSD | 948,355,000Source | 946,346,000Source | 913,712,000Source | 670,035,000Source |
| Other Nonoperating Income (Expense)USD | -133,000Source | -2,170,000Source | -727,000Source | -288,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 380,120,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | 393,280,000Source |
| Proceeds from Stock Options ExercisedUSD | 5,545,000Source | 14,316,000Source | 71,274,000Source | — |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 109,131,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,003,782,000Source | 781,367,000Source | 396,591,000Source | 75,422,000Source |
| Selling, General and Administrative ExpenseUSD | 550,265,000Source | 501,053,000Source | — | — |
| Operating Income (Loss)USD | 55,427,000Source | -164,979,000Source | -517,121,000Source | -594,613,000Source |
| Other Nonoperating Income (Expense)USD | -133,000Source | -2,170,000Source | -727,000Source | -288,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 24,110,000Source | -196,716,000Source | -526,496,000Source | -651,503,000Source |
| Income Tax Expense (Benefit)USD | 1,722,000Source | 1,162,000Source | 2,132,000Source | 669,000Source |
| Net Income (Loss) Attributable to ParentUSD | 22,388,000Source | -197,878,000Source | -528,628,000Source | -652,172,000Source |
| Earnings Per Share, BasicUSD per share | 0.18Source | -1.6Source | -4.45Source | -6.15Source |
| Earnings Per Share, DilutedUSD per share | 0.2Source | -1.6Source | -4.45Source | -6.15Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 126,145,000Source | 123,905,000Source | 118,678,000Source | 106,114,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 129,855,000Source | 123,905,000Source | 118,678,000Source | 106,114,000Source |
| Interest Expense (non-operating)USD | 44,327,000Source | 40,391,000Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 1,722,000Source | 1,162,000Source | 2,132,000Source | 669,000Source |
| General and Administrative ExpenseUSD | — | — | 500,815,000Source | 277,163,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -120,516,000Source | -22,701,000Source | -48,495,000Source | -82,815,000Source |
| Operating ExpensesUSD | 948,355,000Source | 946,346,000Source | 913,712,000Source | 670,035,000Source |
| Research and Development ExpenseUSD | 295,854,000Source | 327,570,000Source | 354,387,000Source | 387,236,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 109,131,000Source | — | — | — |
Filing attachments
d23709dex41.htm · 8-K · 2026-05-14
EX-4.1 4 d23709dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 FIRST SUPPLEMENTAL INDENTURE This First Supplemental Indenture (this “Supplemental Indenture”) is made and entered into as of May 14, 2026, among Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Biogen Inc., a Delaware corporation (“Parent”), and U.S. Bank Trust Company, National Association, as successor in interest to U.S. Bank National Association, as trustee (the “Trustee”). RECITALS WHEREAS, the Company and th…
Read attachment ↗d23709dex991.htm · 8-K · 2026-05-14
EX-99.1 6 d23709dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 May 14, 2026 U.S. Bank Trust Company, National Association Global Corporate Trust One Federal Street, 10th Floor Boston, MA 02110 Attention: James Byrnes The Depository Trust Company Announcements Department 140 58th Street Brooklyn, NY 11220 Attention: Announcement Department Re: Apellis Pharmaceuticals, Inc. – Notice of Supplemental Indenture, Fundamental Change and Make-Whole Fundamental Change to Trust…
Read attachment ↗d132653dex991.htm · 8-K · 2026-03-31
EX-99.1 3 d132653dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of March 31, 2026, is by and among Biogen Inc., a Delaware corporation (“Parent”), Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and each stockholder listed on the signature pages hereto (each, a “Stockholder”). WHEREAS, each Stockholder is, as of the date hereof, the record or benef…
Read attachment ↗d132653dex992.htm · 8-K · 2026-03-31
EX-99.2 4 d132653dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal disease Bri…
Read attachment ↗d19666dex991.htm · 8-K · 2026-01-12
EX-99.1 2 d19666dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Apellis Highlights Commercial Execution and Strategic Priorities at the 44 th Annual J.P. Morgan Healthcare Conference Full-year 2025 preliminary1 U.S. net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe planned in 1H 2026 Strong EMPAVELI® (pegcetacoplan) launch in C3G and primary IC-MPGN continues, with 267 n…
Read attachment ↗d885806dex991.htm · 8-K · 2025-01-13
EX-99.1 2 d885806dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Apellis Highlights Commercial Growth and Strategic Priorities at 43 rd Annual J.P. Morgan Healthcare Conference Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024 $98 million in EMPAVELI® U.S. net product revenues, including $23 million in 4Q 2024 Expects submission of EMPAVELI sNDA for C3G and primary IC…
Read attachment ↗